NEW DELHI, Nov 2: Alembic Pharmaceuticals on Wednesday said it has received final approval from the US health regulator for its generic Mesalamine extended-release capsules indicated for the maintenance of remission of ulcerative colitis in adults.
The approval granted by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Mesalamine Extended-Release Capsules of strength 0.375 g, the company said in a statement.
The approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc’s reference listed drug (RLD), Apriso extended-release capsules, 0.375 g, it added.
The drug has an estimated market size of USD 133 million for the months ended June 2022, Alembic said citing IQVIA data. (PTI)
Follow our WhatsApp channel
